20 Jan 2020 – Positive update on the development of new XF-platform drug formulations
Monday January 20, 2020
Monday January 20, 2020
Collaboration with MedPharm Ltd. delivers data profiling new XFâplatform drug formulations as potential treatments for dermal and ocular infections.
New formulations support a growing pipeline alongside lead drug asset, XF-73, currently in Phase 2b development with data anticipated in mid-2020.
Please see Destiny Pharma press release here